Key result
PCCB linked to increased mitral valve disease risk across blood and cardiac tissues.
Why the study?
Mitochondrial dysfunction is implicated in mitral valve diseases, but specific genetically predicted genes and molecular mechanisms remain undefined.
Observational
Answers are grounded in this paper and cite their sources.
Supports PCCB exploration in mitral valve disease; leaves open causal validation and clinical relevance.
BACKGROUND: Mitochondrial dysfunction is implicated in mitral valve diseases (MVD), but specific genetically predicted genes and molecular mechanisms remain undefined. OBJECTIVE: We aimed to identify mitochondria-related genes driving rheumatic (RMVD) and non-rheumatic (NRMVD) MVD subtypes. METHODS: We performed a multi-omics Mendelian randomization (SMR) study integrating GWAS summary statistics for RMVD and NRMVD with blood DNA methylation (mQTL), gene expression (eQTL), and plasma protein (pQTL) data. Findings were evaluated using cardiac tissue transcriptomics (GTEx), explored in FinnGen, and further assessed by GEO tissue expression and protein-protein interaction (PPI) network analysis. RESULTS: Multi-omics and tissue-specific analyses consistently identified PCCB as a primary candidate risk gene for MVD, demonstrating risk-increasing effects across both blood and cardiac tissues. Independent GEO validation corroborated PCCB upregulation across diseased mitral valve and atrial myocardial tissues. Alongside PCCB, QRSL1 also exhibited consistent risk associations across blood and heart tissues. Exploratory FinnGen validation suggested nominal associations for PCCB and TRMU, though limited by phenotypic heterogeneity. Additionally, we identified a multi-layered epigenetic axis centered on RTN4IP1, where hypermethylation is genetically associated with reduced systemic expression and protein abundance. However, tissue-specific and GEO analyses revealed a paradoxical localized upregulation of RTN4IP1 in diseased atrial myocardium, suggesting a complex, tissue-specific regulatory mechanism. Finally, PPI network analysis demonstrated that these prioritized candidate genes are directly connected to mitochondrial master regulators and OXPHOS complexes. CONCLUSIONS: Our study prioritizes specific mitochondrial genes associated with MVD, identifying PCCB as the most consistent candidate risk gene supported by systemic and localized tissue evidence.
No takes yet. Share an insight, caveat, or question.
Tian et al. (2026) conducted an observational in Mitral valve diseases (rheumatic and non-rheumatic). Genetically predicted expression of mitochondria-related genes was evaluated on Risk of rheumatic and non-rheumatic mitral valve disease. Multi-omics Mendelian randomization identified PCCB as a primary candidate risk gene for mitral valve disease, demonstrating consistent risk-increasing effects across blood and cardiac tissues.
Synapse has enriched 10 related papers. Consider them for comparative context: